The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development ... are urged to get Covid-19 shots each fall.

According to a press release issued by the NIH, the initiative will fund the institute's in-house development of universal ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that ...

R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...

The World Health Organization’s pandemic agreement represents a powerful commitment to global health and security, writes Nina Schwalbe In April in Geneva, as the US withdrew from engagement in global ...